Insider trade

Officer sold ~$509K of UTHR shares in the open market

Traded Dec 1, 2025 · Filed Dec 3, 2025

Why it stands out

United Therapeutics's PRESIDENT AND COO sold $509K of United Therapeutics shares. The filing says it was made under a pre-arranged trading plan.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

OfficerIndirect holding$500K–$1MPre-arranged plan referenced

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$509,005

Shares × reported transaction price

Timing vs results

33 days after results of Oct 29, 2025, 86 days before results of Feb 25, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Planned / mechanical clue

Footnote references a pre-arranged trading plan (Rule 10b5-1)

Only flagged when a footnote says so; never inferred

After	Stock	S&P 500	Difference
7 days	+0.8%	+0.5%	+0.3%
30 days	+3.3%	−0.1%	+3.4%
90 days	+3.7%	−0.5%	+4.2%
180 days	+13.2%	+10.9%	+2.3%

Past results only. Not a forecast.

This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on June 3, 2025.
This transaction was executed in multiple trades at prices ranging from $477.30 to $478.29. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person's family members are beneficiaries, and as to which the Reporting Person has sole investment and voting power.